Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
Saved in:
| Title: | Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. |
|---|---|
| Authors: | Grimshaw, Charles E.1 ched.grimshaw@takeda.com, Jennings, Andy2, Kamran, Ruhi1, Ueno, Hikaru3, Nishigaki, Nobuhiro3, Kosaka, Takuo4, Tani, Akiyoshi4, Sano, Hiroki5, Kinugawa, Yoshinobu5, Koumura, Emiko5, Shi, Lihong1, Takeuchi, Koji3 |
| Source: | PLoS ONE. 6/21/2016, Vol. 11 Issue 6, p1-14. 14p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
